Anti-DCK antibody (1-260 aa) [SRM] (STJ11107359)

SKU:
STJ11107359

Current Stock:
Host: Rabbit
Applications: WB/ELISA
Reactivity: Human/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Clonality: Monoclonal
Clone ID: SRM
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.09% Sodium Azide, 0.05% BSA, 50% Glycerol, pH 7.3.
Purification: Affinity purification
Concentration: Lot specific
Dilution Range: WB:1:2000-1:4000
ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements.
Gene Symbol: DCK
Gene ID: 1633
Uniprot ID: DCK_HUMAN
Immunogen Region: 1-260 aa
Specificity: Recombinant fusion protein containing a sequence corresponding to amino acids 1-260 of human DCK (NP_000779.1).
Immunogen Sequence: MATPPKRSCPSFSASSEGTR IKKISIEGNIAAGKSTFVNI LKQLCEDWEVVPEPVARWCN VQSTQDEFEELTMSQKNGGN VLQMMYEKPERWSFTFQTYA CLSRIRAQLASLNGKLKDAE KPVLFFERSVYSDRYIFASN LYESECMNETEWTIYQDWHD WMNNQFGQSLELDGIIYLQA TPETCLHRIYLRGRNEEQGI PLEYLEKLHYKHESWLLHRT LKTNFDYLQEVPILTLDVN
Post Translational Modifications Phosphorylated and activated in vitro upon phosphorylation at Ser-74 by CSNK1D/CK1.
Function Phosphorylates the deoxyribonucleosides deoxycytidine, deoxyguanosine and deoxyadenosine. Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
Protein Name Deoxycytidine Kinase
Dck
Deoxyadenosine Kinase
Deoxyguanosine Kinase
Database Links Reactome: R-HSA-73614
Reactome: R-HSA-74217
Cellular Localisation Nucleus
Alternative Antibody Names Anti-Deoxycytidine Kinase antibody
Anti-Dck antibody
Anti-Deoxyadenosine Kinase antibody
Anti-Deoxyguanosine Kinase antibody
Anti-DCK antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance